YYYingjiang Ye

Yingjiang Ye

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yingjiang Ye has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Jizhun Zhang

    Department of Gastroenterological Surgery, Peking University People’s Hospital, Beijing, 100044, PR China

    3 shared publications
  • Kewei Jiang

    Department of Gastroenterological Surgery, Peking University People’s Hospital, Beijing, 100044, PR China

    3 shared publications
  • Shan Wang

    Peking University People’s Hospital

    3 shared publications
  • Zhanlong Shen

    Department of Gastroenterological Surgery, Peking University People’s Hospital, Beijing, 100044, PR China

    3 shared publications
  • Liang Lv

    Department of Gastroenterological Surgery, Peking University People’s Hospital, Beijing, 100044, PR China

    2 shared publications
  • Zhidong Gao

    Department of Gastroenterological Surgery, Peking University People’s Hospital, Beijing, 100044, PR China

    2 shared publications

Latest Publications

  • Open Access

    Use of Genome-Wide Association Studies for Cancer Research and Drug Repositioning

    by Jizhun Zhang, Kewei Jiang, Liang Lv, Hui Wang, Zhanlong Shen, Zhidong Gao, Bo Wang, Yang Yang, Yingjiang Ye, Shan Wang

    Although genome-wide association studies have identified many risk loci associated with colorectal cancer, the molecular basis of these associations are still unclear. We aimed to infer biological insights and highlight candidate genes of interest within GWAS risk loci. We used an in silico pipeline based on functional annotation, quantitative trait loci mapping of cis-acting gene, PubMed text-mining, protein-protein interaction studies, genetic overlaps with cancer somatic mutations and knockout mouse phenotypes, and functional enrichment analysis to prioritize the candidate genes at the colorectal cancer risk loci. Based on these analyses, we observed that these genes were the targets of approved therapies for colorectal cancer, and suggested that drugs approved for other indications may be repurposed for the treatment of colorectal cancer. This study highlights the use of publicly available data as a cost effective solution to derive biological insights, and provides an empirical evidence that the molecular basis of colorectal cancer can provide important leads for the discovery of new drugs.


  • Expression QTL-based analyses reveal the mechanisms underlying colorectal cancer predisposition

    by Jizhun Zhang, Kewei Jiang, Zhanlong Shen, Zhidong Gao, Liang Lv, Yingjiang Ye, Shan Wang

    Genome-wide association studies have identified many risk loci associated with colorectal cancer. Strategies integrating biological data sets with GWAS results will provide insights into the roles of risk single-nucleotide polymorphisms. We performed expression quantitative trait locus-based analyses using the information provided in The Cancer Genome Atlas. Analysis of the cis-expression quantitative trait loci (eQTLs) of 18 previously reported colorectal cancer risk loci resulted in the discovery of five variants that were significantly associated with gene expressions. Analysis of the trans-eQTLs identified three risk loci that affect the expression levels of a neighboring transcription factor, MYC. These findings provide a more comprehensive picture of gene expression determinants in colorectal cancer and insights into the underlying biology of risk loci.


  • Evaluation of the seventh AJCC TNM staging system for gastric cancer: a meta-analysis of cohort studies

    by Jizhun Zhang, Yangbing Zhou, Kewei Jiang, Zhanlong Shen, Yingjiang Ye, Shan Wang

    The AJCC seventh edition TNM classification for gastric cancer was released in 2010 and included major revision. Large-volume gastric cancer centers have evaluated the prognostic significance of the new system and obtained paradoxical results. The authors performed a meta-analysis of these studies to evaluate the new classification. Fifteen eligible studies with 38,972 patients were included in the analysis. Hazard ratios (HRs) and associated 95 % confidence intervals were extracted from identified studies. The primary outcome was overall survival. The HRs for the seventh edition T classification and N classification were found to increase steadily and reasonably. The cumulative survival rates of the seventh edition subgroups of T classifications demonstrated obvious differences; meanwhile, the differences between subgroups of N classifications including N3a and N3b categories were also significant. The 5-year survival rates according to the seventh edition TNM staging system were 94.71 % (stage IA), 88.72 % (stage IB), 80.45 % (stage IIA), 67.24 % (stage IIB), 53.68 % (stage IIIA), 37.56 % (stage IIIB), and 21.26 % (stage IIIC), respectively. The results of this study indicate that the seventh edition of the TNM classification was considered valid, although further evaluation was needed for N3a and N3b categories.